Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines the potential of bimatoprost for treating various types of eyelash and eyebrow hypotrichosis, discussing its pharmacological properties but providing no new clinical results.

This article reviews the genetic and psychological aspects of androgenetic alopecia in men and women, reporting no new clinical findings while emphasizing the broad impact of this hair loss condition.

This review examines recent approvals and emerging treatments for androgenetic alopecia, discussing newly approved drugs like Propecia and Rogaine Extra Strength 5%, but without presenting new clinical results.

This study developed a method using HPLC with UV-DAD and ESI-MS detection to identify prohibited substances like minoxidil and hormones in cosmetic products advertised online for hair loss and skin conditions.

This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.

This review discusses the causes of alopecia, including androgenetic alopecia, and potential active ingredients for hair regrowth, but it does not report new clinical results.

AGA is a genetic, hormonal hair loss treated with finasteride, minoxidil, and supplements, but new compounds are being developed.

The researchers reported that pubic hair transplantation surgery may help improve self-esteem in women with pubic atrichosis or hypotrichosis by achieving natural and realistic-looking results.

This study suggested that pubic hair transplantation surgery can effectively address feelings of inferiority in patients with pubic atrichosis or hypotrichosis, achieving a mean graft survival rate of 73.6%.

In this study, researchers overexpressed Lrig3 in mouse skin and observed hair loss linked to changes in skin protein profiles and signaling pathways, suggesting a potential role for Lrig3 in maintaining skin homeostasis.

This study found that follistatin and activin interactions are important for hair follicle development and cycling in mice, suggesting that they may regulate processes involving BMP-2 and its antagonist.

This study observed that follistatin and activin interactions significantly influence hair follicle development in mice, suggesting potential regenerative treatments for alopecia.

This study observed that selectively activating activin in the epidermis of mice enhanced reepithelialization during wound healing without altering the quality of the healed wound.

This study found that coactivating LIN28B and follistatin enhances cochlear supporting cells' ability to regenerate hair cells in neonatal mice by reprogramming them into progenitor-like cells.

This study found that mouse FLRG protein, a secreted glycoprotein, is expressed in certain tissues and plays a role distinct from follistatin during wound healing, suggesting different functions in vivo.

This article discusses the global interest and market presence of biotin-based supplements like Folexin for preventing alopecia, but it reports no new research findings.

Activin A and Follistatin affect how mouse hair follicles grow.

Folliculin slows hair growth, and blocking it might help treat hair loss.

FOL-005 peptide may help treat excessive hair growth safely.

This article reviews the role of factor Xa inhibitors like Rivaroxaban and suggests they may eventually replace vitamin K antagonists, but their side effects require further clarification.

This study explored the secretion and cellular localization of different forms of follistatin and FST-like-3, revealing variable secretion kinetics and possible intracellular roles, particularly for nuclear FSTL3.

In this study, prolonged intravenous Fenoterol infusion was associated with intensive hair growth in most patients, although hormonal changes typically linked to such effects were not observed.

This study identified Activin A and follistatin as key regulators of hair cell differentiation in the mammalian auditory sensory epithelium, with Activin A signaling influencing the timing and pattern of cell differentiation.

This study found that OVOL1-regulated genes, particularly Fst and SFRP1, significantly affect the hair-inducing capacity of neonatal mouse dermal cells.

This study found that GLI2 plays a key role in activating follistatin, an activin/BMP antagonist, in response to hedgehog signaling in human epidermal cells, with implications for hair follicle development and basal cell carcinoma.

In this study, researchers found that reducing FGF20 expression in dermal papilla cells of fine-wool sheep impedes the growth and differentiation of hair follicle stem cells, providing insights into wool trait improvement and regenerative medicine applications.

This study identified the osteopontin-derived peptide, FOL-005, as a potential inhibitor of unwanted human hair growth by promoting catagen development without reducing stem cell numbers or showing toxicity.

This study observed that activin A and its antagonist follistatin influence the differentiation of inner ear hair cells by regulating the expression of the transcription factor ATOH1.

This study found that a newly developed peptide, FOL-005, significantly inhibited hair growth and counteracted minoxidil's effects in organ-cultured human male scalp skin and mouse models, without apparent toxicity.